January 6, 2020 10:47 AM ESTUpdated January 9, 07:32 PM

Phathom Pharmaceuticals snatches up another Celgene exec; True North bets $74M for a stake in Biocon Biologics

ENDPOINTS

→ Ahead of the potential commercialization of vonoprazan, gastrointestinal disease-focused Phathom Pharmaceuticals has brought on another former Celgene exec. Last month the company welcomed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Phathom Pharmaceuticals snatches up another Celgene exec; True North bets $74M for a stake in Biocon Biologics

ENDPOINTS

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?

Phath­om Phar­ma­ceu­ti­cals snatch­es up an­oth­er Cel­gene ex­ec; True North bets $74M for a stake in Bio­con Bi­o­log­ics

ENDPOINTS

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Phathom Pharmaceuticals snatches up another Celgene exec; True North bets $74M for a stake in Biocon Biologics

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?